Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

796 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.
Mikhaeel NG, Heymans MW, Eertink JJ, de Vet HCW, Boellaard R, Dührsen U, Ceriani L, Schmitz C, Wiegers SE, Hüttmann A, Lugtenburg PJ, Zucca E, Zwezerijnen GJC, Hoekstra OS, Zijlstra JM, Barrington SF. Mikhaeel NG, et al. Among authors: schmitz c. J Clin Oncol. 2022 Jul 20;40(21):2352-2360. doi: 10.1200/JCO.21.02063. Epub 2022 Mar 31. J Clin Oncol. 2022. PMID: 35357901 Free PMC article.
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
Eertink JJ, Burggraaff CN, Heymans MW, Dührsen U, Hüttmann A, Schmitz C, Müller S, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Carr R, Czibor S, Györke T, Ceriani L, Zucca E, Hutchings M, Kostakoglu L, Loft A, Fanti S, Wiegers SE, Pieplenbosch S, Boellaard R, Hoekstra OS, Zijlstra JM, de Vet HCW. Eertink JJ, et al. Among authors: schmitz c. Blood Adv. 2021 May 11;5(9):2375-2384. doi: 10.1182/bloodadvances.2021004467. Blood Adv. 2021. PMID: 33944897 Free PMC article.
Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma.
Greuter M, Eertink JJ, Jongeneel G, Dührsen U, Hüttmann A, Schmitz C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Carr R, Györke T, Burggraaff CN, de Vet H, Hoekstra OS, Zijlstra JM, Coupé V; PETRA consortium. Greuter M, et al. Among authors: schmitz c. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):382-392. doi: 10.1016/j.clml.2021.11.008. Epub 2021 Nov 20. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34953740 Free article.
Interim PET in Diffuse Large B-Cell Lymphoma.
Kurch L, Hüttmann A, Georgi TW, Rekowski J, Sabri O, Schmitz C, Kluge R, Dührsen U, Hasenclever D. Kurch L, et al. Among authors: schmitz c. J Nucl Med. 2021 Aug 1;62(8):1068-1074. doi: 10.2967/jnumed.120.255034. Epub 2020 Nov 27. J Nucl Med. 2021. PMID: 33246974 Free article.
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, Jin MC, Sworder BJ, Garofalo A, Shahrokh Esfahani M, Nabet BY, Soo J, Scherer F, Craig AFM, Casasnovas O, Westin JR, Gaidano G, Rossi D, Roschewski M, Wilson WH, Meignan M, Diehn M, Alizadeh AA. Alig S, et al. Among authors: schmitz c. J Clin Oncol. 2021 Aug 10;39(23):2605-2616. doi: 10.1200/JCO.20.02573. Epub 2021 Apr 28. J Clin Oncol. 2021. PMID: 33909455 Free PMC article.
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators. Dührsen U, et al. Among authors: schmitz c. J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11. J Clin Oncol. 2018. PMID: 29750632 Clinical Trial.
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Schmitz C, Rekowski J, Müller SP, Hertenstein B, Franzius C, Ganser A, Bengel FM, Kroschinsky F, Kotzerke J, La Rosée P, Freesmeyer M, Hoeffkes HG, Hertel A, Behringer D, Mesters R, Weckesser M, Mahlmann S, Haberkorn U, Martens U, Prange-Krex G, Brenner W, Giagounidis A, Moeller R, Runde V, Sandmann M, Hautzel H, Wilop S, Krohn T, Dürk H, Heike M, Alashkar F, Brinkmann M, Trenn G, Wacker D, Kreisel-Büstgens C, Bernhard H, Heil G, Larisch R, Kurch L, Jöckel KH, Hoelzer D, Klapper W, Boellaard R, Dührsen U, Hüttmann A. Schmitz C, et al. Hematol Oncol. 2020 Aug;38(3):244-256. doi: 10.1002/hon.2697. Epub 2020 Feb 18. Hematol Oncol. 2020. PMID: 32067259
796 results